http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Nov 2026 11:58:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Nov+02/27272019.html si-local-file:///var/storage/secattach/20261102/27272019.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Nov+02/27272019.html Mon, 02 Nov 2026 11:58:00 -0500 GRFS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Nov+02/27272004.html si-local-file:///var/storage/secattach/20261102/27272004.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Nov+02/27272004.html Mon, 02 Nov 2026 11:55:00 -0500 GRFS http://www.streetinsider.com/Analyst+PT+Change/Grifols%2C+S.A.+%28GRFS%29+PT+Lowered+to+%249+at+JPMorgan/27231304.html JPMorgan analyst James Quigley lowered the price target on Grifols, S.A. (NASDAQ: GRFS) to $9.00 (from $10.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Grifols%2C+S.A.+%28GRFS%29+PT+Lowered+to+%249+at+JPMorgan/27231304.html Mon, 26 Oct 2026 08:38:39 -0500 GRFS http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Grifols+SA+%28GRF%3ASM%29+%28GRFS%29/27027357.html <p>BofA Securities analyst Graham Parry reiterated a Buy rating and EUR13.00 price target on Grifols SA (GRF:SM) (NASDAQ: GRFS).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Grifols+SA+%28GRF%3ASM%29+%28GRFS%29/27027357.html Fri, 04 Sep 2026 06:07:24 -0500 GRFS http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Grifols+SA+%28GRF%3ASM%29+%28GRFS%29/27027357.html <p>BofA Securities analyst Graham Parry reiterated a Buy rating and EUR13.00 price target on Grifols SA (GRF:SM) (NASDAQ: GRFS).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Grifols+SA+%28GRF%3ASM%29+%28GRFS%29/27027357.html Fri, 04 Sep 2026 06:07:24 -0500 GRFS http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0500 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jul+30/26841023.html si-local-file:///var/storage/secattach/20260730/26841023.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jul+30/26841023.html Thu, 30 Jul 2026 10:49:00 -0500 GRF GRFS O.00303353 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jul+30/26841023.html si-local-file:///var/storage/secattach/20260730/26841023.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jul+30/26841023.html Thu, 30 Jul 2026 10:49:00 -0500 GRF GRFS O.00303353